Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Kymera Therapeutics Trading Down 2.4 %
Shares of Kymera Therapeutics stock traded down $1.18 on Tuesday, reaching $47.30. 327,736 shares of the stock were exchanged, compared to its average volume of 627,109. Kymera Therapeutics, Inc. has a 1-year low of $9.60 and a 1-year high of $50.19. The firm has a market capitalization of $2.90 billion, a PE ratio of -19.31 and a beta of 2.22. The business has a fifty day moving average price of $44.57 and a two-hundred day moving average price of $38.89.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The company had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. During the same period in the previous year, the firm posted ($0.67) EPS. Kymera Therapeutics’s revenue was up 55.2% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on KYMR shares. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. B. Riley lifted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Oppenheimer restated an “outperform” rating and set a $52.00 target price on shares of Kymera Therapeutics in a report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Finally, Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $48.67.
Read Our Latest Research Report on KYMR
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Kymera Therapeutics
- What is the Australian Securities Exchange (ASX)
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is a buyback in stocks? A comprehensive guide for investors
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.